Mounjaro (Tirzepatide) Dual action: targets both GLP-1 and GIP receptors Strong appetite suppression & improved blood sugar control Clinical trials show average body weight loss up to 22.5% over 72 weeks Wegovy (Semaglutide) Targets GLP-1 receptors only Licensed in the UK for obesity and cardiovascular protection STEP trials show 1521% body weight loss A new 7.2mg dose is expected in late 2025, with results potentially matching Mounjaro Both treatments are once-weekly injections, prescribed alongside healthy diet and lifestyle changes
The condition occurs when the small blood vessels supplying the optic nerve head become blocked or experience inadequate perfusion, leading to ischemic damage
A follow-up phase 2 study reported minimal adverse effects associated with this therapy (Stein et al., 2019), and there are several clinical trials further investigating this protein (NCT05234775, NCT04797247, NCT05004675, NCT03545438, NCT04034485, NCT04790513, NCT04806893, NCT04797104, NCT04798430, NCT03549260)
These peptides have their ends joined by chemical bridges , making them less flexible and harder for enzymes to break down
Appearance: White powder
Trong bi vit ny, dc s Lu Vn Hong gii thiu n cc bn sn phm L-Glutathione (Reduced) 500mg Puritans Pride c sn xut bi Puritans Pride, Inc, c s ng k lu hnh ti Vit Nam l 4842/2019/KSP
